When does ULTRALIFE CORP (ULBI) report earnings?
ULTRALIFE CORP (ULBI) will report earnings on 2026-05-07.
ULTRALIFE CORP (ULBI) Forecast, Price Target & Analyst Ratings
NASDAQ:ULBI • US9038991025
Current stock price
6.55 USD
+0.12 (+1.87%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ULTRALIFE CORP (ULBI).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 7, 2026
- Period
- Q1 / 2026
- EPS Estimate
- $0.16
- Revenue Estimate
- 53.448M
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of $6.55 to mean target of N/A, Based on 7 analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.86%
ULBI was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about ULBI.
In the previous month the buy percentage consensus was at a similar level.
ULBI was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-11-15 | Benchmark | Reiterate | Buy -> Buy |
| 2024-06-27 | Benchmark | Maintains | Buy -> Buy |
| 2024-03-05 | Benchmark | Maintains | Buy -> Buy |
| 2023-08-08 | Benchmark | Reiterate | Buy -> Buy |
| 2021-03-26 | Benchmark | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 7, 2026
- Period
- Q1 / 2026
- EPS Estimate
- $0.16
- Revenue Estimate
- 53.448M
- Revenue Q2Q
- 5.32%
- EPS Q2Q
- 25.54%
- Number of Analysts
- 3
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.00%
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
ULBI is expected to report earnings on 5/7/2026. The consensus EPS estimate for the next earnings is 0.16 USD and the consensus revenue estimate is 53.45M USD.
The next earnings revenue estimate has been revised downward by 0% in the past 3 months.
Full Analyst Estimates 2026
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|
| Revenue YoY % growth | 158.644M 20.37% | 164.456M 3.66% | 191.159M 16.24% | 229.4M 20.00% | |
| EBITDA YoY % growth | 13.386M 193.55% | 15.416M 15.17% | N/A 50.86% | 25.296M 8.77% | |
| EBIT YoY % growth | 9.475M 9,375.00% | 11.259M 18.83% | 6.279M -44.23% | 19.278M 207.02% | |
| Operating Margin | 5.97% | 6.85% | 3.28% | 8.40% | |
| EPS YoY % growth | 0.56 1,020.00% | 0.46 -17.86% | 0.25 -45.65% | 0.95 279.44% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | 0.16 25.54% | 0.21 206.00% | 0.26 464.29% | 0.31 155.00% |
| Revenue Q2Q % growth | 53.448M 5.32% | 56.1M 15.52% | 57.12M 31.70% | 62.73M 29.39% |
| EBITDA Q2Q % growth | 6.018M 23.34% | 6.018M 16.49% | 6.63M 84.89% | 6.732M 11.86% |
| EBIT Q2Q % growth | 4.182M 18.67% | 4.284M 79.02% | 4.794M 891.09% | 6.018M 282.10% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
ULTRALIFE CORP / ULBI Forecast FAQ
What are the consensus estimates for ULBI stock next earnings?
The consensus EPS estimate for the next earnings of ULTRALIFE CORP (ULBI) is 0.16 USD and the consensus revenue estimate is 53.45M USD.
What is the consensus rating for ULBI stock?
The consensus rating for ULTRALIFE CORP (ULBI) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.